

This policy applies to the following:

Standard Control (SF)	Managed Medicaid Template (MMT)	ACSF Chart (ACSFC)	Medical Benefit	✓	Medicare Part B	Reference #
Standard Control – Choice (SCCF)	Marketplace (MF)	SF Chart (SFC)	Medical: Advanced Biosimilars First	✓	Medicare Part B: Advanced Biosimilars First	5826-D
Preferred Drug Plan Design (PDPD)	Aetna Health Exchange (AHE)	VF Chart (VFC)	Medical Benefit: Managed Medicaid			
Advanced Control Specialty (ACSF)	IVL	New to Market (NTM)	Medical Benefit: Add-on			
Advanced Control Specialty – Choice (ACSCF)	Value (VF)					

EXCEPTIONS CRITERIA OSTEOPOROSIS

PREFERRED PRODUCTS: PROLIA AND ZOLEDRONIC ACID

POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the osteoporosis products specified in this policy. Coverage for the targeted product is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to members who are new to treatment with a targeted product for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Osteoporosis Products

	Products
Preferred*	<ul style="list-style-type: none"> • Prolia (denosumab) • zoledronic acid
Targeted	<ul style="list-style-type: none"> • Evenity (romosozumab-aqqg)

*: Medications considered formulary or preferred on your plan may still require a clinical prior authorization review

II. EXCEPTION CRITERIA

This program applies to members requesting treatment for an indication that is FDA-approved for any of the preferred products.

Postmenopausal Osteoporosis

Coverage for a targeted product is provided when any of the following criteria are met:

- Member has received treatment with the targeted product in the past 365 days.
- Member has a documented inadequate response to both of the preferred products.
- Member has a documented intolerable adverse event or contraindication to both of the preferred products. (e.g., creatinine clearance less than 35 mL/min for zoledronic acid).

REFERENCES

- Evenity [package insert]. Thousand Oaks, CA: Amgen, Inc.; April 2020.

Osteoporosis

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

This policy applies to the following:

	Standard Control (SF)		Managed Medicaid Template (MMT)		ACSF Chart (ACSFC)		Medical Benefit	✓	Medicare Part B
	Standard Control – Choice (SCCF)		Marketplace (MF)		SF Chart (SFC)		Medical: Advanced Biosimilars First	✓	Medicare Part B: Advanced Biosimilars First
	Preferred Drug Plan Design (PDPD)		Aetna Health Exchange (AHE)		VF Chart (VFC)		Medical Benefit: Managed Medicaid		
	Advanced Control Specialty (ACSF)		IVL		New to Market (NTM)		Medical Benefit: Add-on		
	Advanced Control Specialty – Choice (ACSCF)		Value (VF)						

Reference #
5826-D

2. Prolia [package insert]. Thousand Oaks, CA: Amgen Inc.; January 2024.
3. Zoledronic acid [package insert]. Princeton, NJ: Fosun Pharma USA, Inc.; June 2023.